Physician profile
Ashok V Patel
NPI 1417030230
$7,437.21
in general payments reported to CMS, 2019-2025
28 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,556 · 2020: $242 · 2021: $1,080 · 2022: $1,282 · 2023: $1,390 · 2024: $1,252 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,161.54 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,048.43 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Biogen, INC. | $1,032.93 | 2019-2023 | Tysabri, Vumerity, Tecfidera |
| Novartis Pharmaceuticals Corporation | $786.52 | 2019-2024 | |
| Genentech, INC. | $666.74 | 2019-2024 | Ocrevus |
| Ucb, INC. | $330.37 | 2023-2025 | Zilbrysq |
| Argenx US, INC. | $301.89 | 2023-2024 | Vyvgart |
| Amgen INC. | $214.41 | 2019 | |
| Abbott Laboratories | $168.74 | 2022 | |
| Tg Therapeutics, INC. | $148.03 | 2023 | |
| Mdd US Operations, LLC | $145.36 | 2019-2024 | Gocovri |
| E.R. Squibb & Sons, L.L.C. | $131.08 | 2020-2023 | Zeposia |
| Csl Behring | $125.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Celgene Corporation | $123.71 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $102.60 | 2024 | Rexulti |
| Impel Pharmaceuticals INC. | $101.32 | 2022 | |
| Genzyme Corporation | $99.19 | 2019 | |
| Lundbeck LLC | $96.54 | 2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $89.10 | 2022 | |
| Genentech USA, INC. | $80.80 | 2019 | |
| Eisai INC. | $73.93 | 2022 | |
| Janssen Scientific Affairs, LLC | $69.95 | 2025 | |
| Alexion Pharmaceuticals, INC. | $65.61 | 2019 | |
| Lilly USA, LLC | $59.26 | 2020 | |
| Sk Life Science, INC. | $49.82 | 2020 | |
| Pfizer INC. | $25.64 | 2020-2021 | |
| Allergan, INC. | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.